H2 Global Group is strengthening its position as a European technology group connecting capital with clinically validated healthcare innovations. A prime example is VR LIFE and its flagship MDR-certified medical device, VR Vitalis Pro.

”We are opening the door to U.S. and global partners who recognize this structural shift and want to capitalize on it.” — David Marsalek, CEO and Founder of H2 Global Group

Following a recent $650,000 seed round backed by institutional investors, the implied value of H2 Global Group’s original investment in VR LIFE more than doubled in under three years, reaching approximately $1.38 million. To capitalize on its established European clinical footprint across more than 40 healthcare facilities, VR LIFE is now preparing for FDA certification to support a planned entry into the U.S. market.

Beyond investments, H2 Global Group is expanding its proprietary intellectual property through its subsidiary, H2 Medical Technologies. The Group has developed a patent-pending therapeutic platform combining molecular hydrogen with virtual reality for pulmonary rehabilitation. Following approval from the Czech State Institute for Drug Control (SÚKL) in January 2026, the company entered the registration phase for the world’s first medical device utilizing molecular hydrogen.

With a current pre-money valuation of approximately $67 million, H2 Global Group is pursuing a strategic objective of achieving a transaction value between $500 million and $1.5 billion within three years.

“We are building a vertically integrated MedTech ecosystem that brings together breakthrough Japanese science, European clinical validation, and global capital to confront some of the most urgent healthcare challenges of our time,” said David Marsalek, CEO and Founder of H2 Global Group. “We are advancing non-invasive solutions aimed at cognitive decline, Alzheimer’s disease, mild cognitive impairment, systemic inflammation, pulmonary rehabilitation, and the escalating quality-of-life crisis associated with aging populations."

Marsalek added, "We are opening the door to U.S. and global partners who recognize this structural shift and want to capitalize on it.”

The company's therapeutic focus areas represent a combined addressable market exceeding $150 billion, including the $18 billion Alzheimer's and MCI market and the $110 billion anti-inflammatory therapeutics sector.